Aurobindo Pharma subsidiary terminates biosimilar agreement with BioFactura

On December 27, 2025, Aurobindo Pharma Limited announced the termination of an agreement between its subsidiary, CuraTeQ Biologics Private Limited, and BioFactura Inc, USA. The agreement, originally executed on July 7, 2023, pertained to the commercialization of BFI-751, a proposed ustekinumab biosimilar product, and granted CuraTeQ global manufacturing rights.

The decision to terminate the license agreement is aligned with CuraTeQ's strategic portfolio prioritization. Aurobindo Pharma stated that this termination is not expected to have a material impact on the company's overall biosimilars strategy.

The original agreement outlined a profit-sharing arrangement and license fees payable to BioFactura, spread across various milestones. The termination was officially confirmed through a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.